Cycle control with a 21-day compared with a 24-day oral contraceptive pill: A randomized controlled trial

Obstetrics and Gynecology

Volumn 114, Issue 6, 2009, Pages 1205-1212

  Kaunitz, Andrew M ^a   Burkman, Ronald T ^a   Fisher, Alan C ^a   Laguardia, Katherine D ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORGESTIMATE; ALDOSTERONE ANTAGONIST; ANDROSTANE DERIVATIVE; DROSPIRENONE; DRUG DERIVATIVE; ETHINYLESTRADIOL; NORGESTIMATE, ETHINYL ESTRADIOL DRUG COMBINATION; NORGESTREL; ORAL CONTRACEPTIVE AGENT;

ADULT; AMENORRHEA; ARTICLE; BREAKTHROUGH BLEEDING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN EXPERIMENT; INTERACTIVE VOICE RESPONSE SYSTEM; IRRITABILITY; LUMBAR DISK HERNIA; LUNG EMBOLISM; MENSTRUAL CYCLE; MENSTRUATION; MOOD; NAUSEA AND VOMITING; NORMAL HUMAN; OPEN STUDY; ORAL CONTRACEPTION; OVARY CYST; PREGNANCY TEST; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPOTTING; TREATMENT DURATION; UNITED STATES; UTERUS MYOMA; WITHDRAWAL BLEEDING; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; METRORRHAGIA; MULTICENTER STUDY;

ADULT; ALDOSTERONE ANTAGONISTS; ANDROSTENES; CONTRACEPTIVES, ORAL, COMBINED; ETHINYL ESTRADIOL; FEMALE; HUMANS; MENSTRUAL CYCLE; METRORRHAGIA; NORGESTREL; YOUNG ADULT;

EID: 73349114346     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3181beab47     Document Type: Article

References (18)

1. Blumenthal PD, Edelman A. Hormonal contraception. Obstet Gynecol 2008;112:670-684
2. Kaunitz AM. Clinical practice. Hormonal contraception in women of older reproductive age. N Engl J Med 2008;358: 1262-1270
3. Gallo MF, Nanda K, Grimes DA, Lopez LM, Schulz KF. 20 microg versus >20 microg estrogen in combined oral contraceptives for contraception. The Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No.: CD003989. DOI: 10.1002/14651858.CD003989.pub3.
4. Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception 1995;51:283-288
5. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation. A prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998;179:577-582
6. Sabatini R, Cagiano R. Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Contraception 2006;74:220-223
7. Nakajima ST, Archer DF, Ellman H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 /ng (Loestrin 24 Fe). Contraception 2007;75:16-22.
8. Hampton RM, Short M, Bieber E, Bouchard C, Ayotte N, Shangold G, et al. Comparison of a novel norgestimate/ethinyl estradiol contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20. Contraception 2001;63:289-295
9. Bachmann G, Sulak PJ, Sampson-Landers C, Benda N, MarrJ. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 /ng ethinylestradiol and 3 mg drospirenone. Contraception 2004;70:191-198
10. Klipping C, MarrJ. Effects of two combined oral contraceptives containing ethinyl estradiol 20 /ng combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception 2005;71:409-416
11. Mishell DR Jr, Guillebaud J, Westhoff C, Nelson AL, Kaunitz AM, Trussell J, et al. Combined hormonal contraceptive trials: variable data collection and bleeding assessment methodologies influence study outcomes and physician perceptions. Contraception 2007;75:4-10.
12. Mishell DR Jr, Guillebaud J, Westhoff C, Nelson AL, Kaunitz AM, Trussell J, et al. Recommendations for standardization of data collection and analysis of bleeding in combined hormone contraceptive trials. Contraception 2007;75:11-15
13. U.S. Food and Drug Administration. Advisory Committee for Reproductive Health Drugs. Food and Drug Administration Center for Drug Evaluation and Research Volumes I and II. Available at: http://www.fda.gov/ohrms/dockets/ac/ cder07.htm. Retrieved May 6, 2009.
14. DRSP/EE Study 303860, NDA 21-676. http://www.accessdata. fda.gov/drugsatfda-docs/nda/2006/021676s000-MEDR- pt1.pdf. Retrieved August 17, 2009.
15. NGM/EE Study NRGLOW-OC-001, NDA 21-241. http:// www.accessdata.fda.gov/ drugsatfda-docs/na/2002/021241- S000-ORTHO-TRI-CYCLENE-MEDR.pdf. Retrieved August 17, 2009.
16. Belsey EM, Machin D, d'Arcangues D. The analysis of vaginal bleeding patterns induced by fertility regulating methods. Contraception 1986;34:253-260
17. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice E6(R1). Current Step 4 version. Available at: http://www.emea.europa.eu/pdfs/human/ich/013595en.pdf. Retrieved June 7, 2009.
18. Hampton RM, Fisher AC, Pagano S, LaGuardia KD. Scheduled and unscheduled bleeding patterns with two combined hormonal contraceptives: application of new recommendations for standardization. Fertil Steril 2009;92:434-440